tm
Seeing Is Believing
tm
Seeing Is Believing
MNPR is currently covered by 10 analysts with an average price target of $81.31. This is a potential upside of $22.07 (37.26%) from yesterday's end of day stock price of $59.24.
Monopar Therapeutics's activity chart (see below) currently has 16 price targets and 37 ratings on display. The stock rating distribution of MNPR is 95.24% BUY and 4.76% HOLD.
Analysts average stock forecasts to be materialized ratio is 80.48% with an average time for these price targets to be met of 375.14 days.
Highest price target for MNPR is $115, Lowest price target is $40, average price target is $86.
Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 29-Jan-2026. First documented stock forecast 03-Feb-2020.
Currently out of the existing stock ratings of MNPR, 20 are a BUY (95.24%), 1 are a HOLD (4.76%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 23-Jun-2025
$100
$42.25 (73.16%)
$85
15 days ago
(29-Jan-2026)
4/5 (80%)
$32.66 (48.50%)
33
Buy Since 03-Sep-2025
$115
$57.25 (99.13%)
$77
4 months 11 days ago
(02-Oct-2025)
1/2 (50%)
$17.79 (18.30%)
22
Buy Since 19-Mar-2025
$95
$37.25 (64.50%)
$76
4 months 19 days ago
(25-Sep-2025)
2/2 (100%)
$17.56 (22.68%)
99
Buy
$80
$-7.82 (-8.90%)
$72
5 months 10 days ago
(02-Sep-2025)
2/2 (100%)
$43.79 (120.93%)
142
Buy Since 16-Aug-2022
$40
$-17.75 (-30.74%)
$40
10 months 12 days ago
(01-Apr-2025)
7/7 (100%)
$6.57 (19.65%)
316
What is MNPR (Monopar Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on MNPR (Monopar Therapeutics) with a proven track record?
Which analyst has the current lower performing score on MNPR (Monopar Therapeutics) with a proven track record?
Which analyst has the most public recommendations on MNPR (Monopar Therapeutics)?
Which analyst is the currently most bullish on MNPR (Monopar Therapeutics)?
Which analyst is the currently most reserved on MNPR (Monopar Therapeutics)?
